Evidence map›Paper›PMID 32871498›Full record

ArticleBiosensors & bioelectronics2020

Extracellular vesicles on demand (EVOD) chip for screening and quantification of cancer-associated extracellular vesicles.

Yoon-Tae Kang, Thomas Hadlock, Shruti Jolly, Sunitha Nagrath

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors & bioelectronics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Isolation and characterization of extracellular vesicles and future directions in diagnosis and therapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yoon-Tae KangDepartment of Chemical Engineering and Biointerface Institute, University of Michigan, 2800 Plymouth Road, NCRC B10-A184, Ann Arbor, MI, 48109, USA.
Thomas HadlockDepartment of Chemical Engineering and Biointerface Institute, University of Michigan, 2800 Plymouth Road, NCRC B10-A184, Ann Arbor, MI, 48109, USA.
Shruti JollyRadiation of Oncology, University of Hospital, University of Michigan, 1500 E Medical Center Dr. Ann Arbor, MI, 48109, USA.
Sunitha NagrathDepartment of Chemical Engineering and Biointerface Institute, University of Michigan, 2800 Plymouth Road, NCRC B10-A184, Ann Arbor, MI, 48109, USA; Roger Cancer Center, University of Michigan, 1500 E Medical Center Dr. Ann Arbor, 48109, USA. Electronic address: snagrath@umich.edu.
BioSurfaces (United States) · USUniversity of Michigan–Ann Arbor · US

Funding

Label free microfluidic isolation, characterization and ex vivo expansion of CTCsR01CA208335 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NAGRATH, SUNITHA · 2017 to 2021
$2.8M
High Throughput GO Chip isolation of Lung CTCs for Molecular Diagnosis and Drug TestingR33CA202867 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NAGRATH, SUNITHA, RAMNATH, NITHYA · 2016 to 2018
$1.0M
NCI NIH HHS R01 CA208335NCI NIH HHS R33 CA202867
6 · The paper itself

Abstract

While significant advancements have been made in cancer therapeutics and treatments, early disease detection and diagnosis remains critical to ensuring favorable outcomes for patients. To that end, we propose a microfluidic based approach to the sensitive detection of an intriguing cancer biomarker, extracellular vesicles (EVs). Our extracellular vesicles on demand (EVOD) chip utilizes a catalyst-free click chemistry to rapidly and specifically isolate EVs of interest. This specific isolation is followed by subsequent dithiothreitol release of the isolated EVs for downstream functional analysis. This joint isolation and release provide a powerful tool for the screening and quantification of EVs of interest. By incorporating antibodies against cancer associated surface proteins into the click-chemistry, we were able to selectively recover cancer-associated exosomes, allowing for important insights into patient disease. This platform was also tested using non-small cell lung cancer (NSCLC) patient samples, where anti-epidermal growth factor receptor (EGFR) assisted platform were able to selectively isolate and release 76% more exosomes from NSCLC patients than from healthy donors. This matches the previously reported higher EGFR expression commonly found in NSCLC EVs. Through its rapid isolation kinetics and adaptability in marker targeting, the EVOD device provides a highly versatile liquid biopsy platform for clinicians to use in the fight against cancer.

Indexed as

Biosensing TechniquesCarcinoma, Non-Small-Cell LungExtracellular VesiclesLung NeoplasmsEarly Detection of CancerHumansClick chemistryExtracellular vesiclesImmunoaffinity isolationMicrofluidicsVesicle release

Identifiers

PMID32871498
PMCPMC9475444
OpenAlexW3081185011

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.